Compare MCY & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCY | SRRK |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.8B |
| IPO Year | 1995 | 2018 |
| Metric | MCY | SRRK |
|---|---|---|
| Price | $106.15 | $58.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $100.00 | $56.17 |
| AVG Volume (30 Days) | 246.8K | ★ 997.7K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 15.62 | N/A |
| EPS | ★ 8.20 | N/A |
| Revenue | ★ $5,992,468,000.00 | N/A |
| Revenue This Year | $5.16 | N/A |
| Revenue Next Year | $5.59 | $534.24 |
| P/E Ratio | $12.89 | ★ N/A |
| Revenue Growth | ★ 9.44 | N/A |
| 52 Week Low | $74.29 | $27.07 |
| 52 Week High | $113.06 | $58.49 |
| Indicator | MCY | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 49.68 | 65.96 |
| Support Level | $84.77 | $45.81 |
| Resistance Level | $111.99 | $58.49 |
| Average True Range (ATR) | 2.56 | 2.50 |
| MACD | -0.21 | 0.72 |
| Stochastic Oscillator | 32.96 | 94.37 |
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The company offers the following types of automobile coverage: collision, property damage, bodily injury (BI), comprehensive, personal injury protection (PIP), underinsured and uninsured motorist, and other hazards. Additionally, it offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages. The company has one reportable business segment, the Property and Casualty business segment.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.